AdAlta presents at Investor Summit

AdAlta Limited (ASX: 1AD) CEO and Managing Director, Dr Tim Oldham presented at the Investor Summit on 1 June, 2023.

The webinar presentation covers how AdAlta, as a clinical stage biotech company is developing a pipeline of next generation therapeutics to treat challenging diseases in fibrosis and oncology. It covers AdAlta’s three partnering streams:
1️⃣ out-licensing AD-214;
2️⃣ partnering the i-body platform; and
3️⃣ evaluating complimentary technologies and products.

To watch the webinar, click on the below image.

AdAlta presents at Twilight Investor Briefing

On Thursday 25 May, AdAlta’s CEO and Managing Director, Dr Tim Oldham presented at an in-person Twilight Investor briefing in Melbourne along with our collaboration partner, Carina Biotech’s CEO, Dr Deborah Rathjen.

Dr Oldham explained AdAlta’s current areas of strategic focus, including lead program AD-214, our CAR-T cell therapy program and progress on partnering opportunities.

The event was hosted by Peak Asset Management, the corporate advisor for AdAlta’s recent Rights Offer.

To watch a recording of the event (presentation slides and audio), click below.

The presentation slides can also be viewed by CLICKING HERE

AdAlta Rights Offer webinar recording, Wednesday 3 May 2023

AdAlta’s CEO and Managing Director Dr Tim Oldham held a webinar on Wednesday 3 May 2023 to discuss the recently launched A$3.15 million non-renounceable rights offer (Offer) to shareholders. During the webinar, Tim covered AdAlta’s four strategic objectives and various milestones the Company is working towards, including an early return to the clinic for AD-214.

The strategic objectives to create and crystallise value from our i-body platform include:

  1. Realising the value of AD-214, including the generation of new clinical data for partnering
  2. Extending the i-CAR programs
  3. Progressing i-PET development
  4. Investing in the i-bodyTM platform internally and through synergistic technology and product collaborations 

To watch a recording of the webcast, please CLICK HERE or on the image below.

The presentation slides can also be found HERE.

For more information on the Rights Offer, including key dates and terms, please CLICK HERE to visit the Rights Offer page.

AdAlta thanks investors for their ongoing interest and support. We will continue to provide updates as we reach the timetable deadlines for the Offer.

Bioshares: AdAlta prioritises IV formulation for AD-214

Bioshares have recently reported on AdAlta’s strategy update for its lead drug candidate AD-214 and plans for returning AD-214 to clinical studies.

The report covers the background on AdAlta’s 2021 announcement about plans to add an inhaled formulation for AD-214 to the existing intravenous route and the three keys reasons for the decision to prioritise the intravenous formulation for next clinical trials.

To read the report CLICK HERE.